ABSTRACT
Luteal phase support is becoming a highly personalized treatment based on each stimulation protocol and patient characteristics. After the application of human chorionic gonadotrophin (hCG) for final oocyte maturation, the vaginal route for progesterone administration is sufficient to maintain an adequate luteal phase support. Luteolysis after gonadotropin releasing hormone (GnRH) agonist trigger is patient specific and not always severe. According to the progesterone level, individualized luteal phase support with low dosages of hCG can be applied without the risk of ovarian hyperstimulation syndrome (OHSS) development. It is the task of the reproductive medicine specialist to individualize luteal phase support according to the patient's specific characteristics, needs, and desires and the type of treatment performed.
